Evidence map›Paper›PMID 31587134›Full record

Trial reportInternational journal of clinical oncology2020

Retrospective study on bevacizumab in the treatment of non-small cell lung cancer with brain metastases.

Zhen Wang, Jin-Ji Yang, Hai-Yan Tu, Hong-Hong Yan, Yi-Long Wu

Abstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in International journal of clinical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. [Anti-angiogenesis in Lung Cancer: Current Situation, Progress and Confusion].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2022
    Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Zhen WangGuangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangdong Lung Cancer Institute, 106 Zhongshan 2nd Road, Guangzhou, 510080, People's Republic of China.
Jin-Ji YangGuangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangdong Lung Cancer Institute, 106 Zhongshan 2nd Road, Guangzhou, 510080, People's Republic of China.
Hai-Yan TuGuangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangdong Lung Cancer Institute, 106 Zhongshan 2nd Road, Guangzhou, 510080, People's Republic of China.
Hong-Hong YanGuangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangdong Lung Cancer Institute, 106 Zhongshan 2nd Road, Guangzhou, 510080, People's Republic of China.
Yi-Long WuGuangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangdong Lung Cancer Institute, 106 Zhongshan 2nd Road, Guangzhou, 510080, People's Republic of China. syylwu@live.cn.
Guangdong Academy of Medical Sciences · CNGuangdong Provincial People's Hospital · CN

Funding

Guangzhou Science and Technology Project grant 201804010477National Health and Family Control Committee grant 201402031
6 · The paper itself

Abstract

backgroundBevacizumab was demonstrated to have efficacy in patients with non-small cell lung cancer (NSCLC) and brain metastases. However, cerebral toxicities were a major concern. This study aims to investigate the efficacy and risk factors of toxicity of bevacizumab in brain metastases.

methodsAll patients with advanced NSCLC hospitalized in our institute were screened and only those, who underwent bevacizumab administration after the diagnosis of brain metastases, were included.

resultsFifty-one patients, who were treatment naïve or pretreated prior to bevacizumab regimens, were enrolled. Regardless of treatment lines, the objective response rate (ORR) was 62.7% (32/51), progression free survival (PFS) and overall survival were 6.2 months (95%CI, 5.0-7.4) and 14.0 months (95%CI, 9.6-18.4), respectively, and intracranial PFS was 7.8 months (95%CI, 7.1-8.5). For 41 patients with measurable brain metastatic lesions, the intracranial ORR was 46.3% (19/41). Ten patients (19.6%, 10/51) experienced cerebral toxicities (seven cases of grade 1 and three cases of grade 3), including cerebral or intratumoral hemorrhage and ischemic stroke. Cardiovascular disease was the risk factor contributing to cerebral toxicities (OR 16.645; 95%CI, 2.443-113.430; P = 0.004).

conclusionsThis retrospective study shows that bevacizumab has efficacy and favorable toxicity in patients with NSCLC and brain metastases and cardiovascular disease might be a risk factor for cerebral toxicity.

Indexed as

AdultAgedAntineoplastic Combined Chemotherapy ProtocolsBevacizumabBrain DiseasesBrain NeoplasmsCarcinoma, Non-Small-Cell LungFemaleHumansLung NeoplasmsMaleMiddle AgedRetrospective StudiesTreatment OutcomeBevacizumabBevacizumabBrain metastasisLung cancer

Identifiers

PMID31587134
OpenAlexW2978379152

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.